Current situation and progress of drugs for reducing intraocular pressure

P Liu, F Wang, Y Song, M Wang… - … advances in chronic …, 2022 - journals.sagepub.com
Glaucoma, the most common cause of irreversible blindness worldwide, usually causes
characteristic optic nerve damage. Pathological intraocular pressure (IOP) elevation is a …

The latest drugs in development that reduce intraocular pressure in ocular hypertension and glaucoma

V Jayanetti, S Sandhu, JA Lusthaus - Journal of Experimental …, 2020 - Taylor & Francis
Glaucoma causes irreversible vision loss, with elevated intraocular pressure (IOP) being the
only known modifiable risk factor. There are a variety of medical and interventional options …

New pharmacotherapy for the treatment of glaucoma

EM Schehlein, G Novack, AL Robin - Expert Opinion on …, 2017 - Taylor & Francis
Introduction: Glaucoma is the second leading cause of blindness in the world and current
pharmacotherapies for glaucoma have remained relatively unchanged (with the exception of …

Investigational and experimental drugs for intraocular pressure reduction in ocular hypertension and glaucoma

JA Lusthaus, I Goldberg - Expert Opinion on Investigational Drugs, 2016 - Taylor & Francis
Introduction: Intraocular pressure (IOP) is the most significant modifiable risk factor to
prevent onset or progression of glaucoma. Glaucoma prevalence continues to increase …

The management of glaucoma and intraocular hypertension: current approaches and recent advances

RJ Noecker - Therapeutics and clinical risk management, 2006 - Taylor & Francis
In the last decade, numerous novel ocular hypotensive agents have been introduced for the
control of intraocular pressure (IOP). Clinicians now have more options than ever in the …

Glaucoma-intraocular pressure reduction

AS Huang, L Minasyan, RN Weinreb - Pharmacologic Therapy of Ocular …, 2017 - Springer
Medical treatment is a mainstay for the management of glaucoma (Realini 2011; Marquis
and Whitson 2005; Hoyng and van Beek 2000). Intraocular pressure (IOP) lowering has …

Recently approved drugs for lowering and controlling intraocular pressure to reduce vision loss in ocular hypertensive and glaucoma patients

NA Sharif - Pharmaceuticals, 2023 - mdpi.com
Serious vision loss occurs in patients affected by chronically raised intraocular pressure
(IOP), a characteristic of many forms of glaucoma where damage to the optic nerve …

Pharmacotherapy of glaucoma

D Schmidl, L Schmetterer, G Garhöfer… - Journal of Ocular …, 2015 - liebertpub.com
Glaucoma is a group of diseases involving the optic nerve and associated structures, which
is characterized by progressive visual field loss and typical changes of the optic nerve head …

Current and new pharmacotherapeutic approaches for glaucoma

WS Shalaby, V Shankar, R Razeghinejad… - Expert Opinion on …, 2020 - Taylor & Francis
Introduction Glaucoma is the leading cause of irreversible blindness worldwide. Medical
therapy is the main line of treatment of open-angle glaucoma (OAG) and ocular …

Achieving low target pressures with today's glaucoma medications

L Cantor - Survey of ophthalmology, 2003 - Elsevier
In the 21st century there are more highly effective medical management options for
glaucoma than there were in the 1980s and 1990s. In deciding among them, the clinician's …